MiniMed develops integrated diabetes management systems for insulin-dependent patients. The company’s primary product is the MiniMed 780G automated insulin delivery system, which integrates an insulin pump, continuous glucose monitoring sensors, and algorithms to automate dosing. MiniMed also sells the MiniMed Go smart insulin pen for patients who prefer injections. The business uses a razor-and-blades model where durable pump installations drive recurring sales of consumables like sensors, infusion sets, and reservoirs. These consumables and software subscriptions generate the majority of revenue. MiniMed captures more revenue per customer than peers by manufacturing and selling every component of the system internally. The company markets to healthcare providers who prescribe devices to patients with Type 1 or Type 2 diabetes. MiniMed distributes products through durable medical equipment and pharmacy channels. Growth strategies focus on deeper penetration of the Type 2 market and launching new hardware like the MiniMed Fit patch pump. MiniMed also collaborates with Abbott to incorporate third-party sensors and is developing the Vivera algorithm to eliminate manual dosing. The company operates manufacturing facilities in California and Puerto Rico to support a global user base across more than 80 countries.